Cogent Biosciences, Inc. income statement COGT

Annual Quarterly

It recorded a net loss of $328.9 million. Diluted earnings per share were -$2.16.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018
Revenue	—	—	—	—	—	8 -65.0%	22 +131.1%	10
Research and development	270 +16.0%	233 +33.9%	174 +42.9%	122 +117.5%	56 +117.2%	26 -41.1%	44 +14.2%	38
Selling, general and administrative	64 +46.9%	43 +25.9%	34 +31.1%	26 +33.5%	20 +12.7%	17 +58.8%	11 +47.1%	7
Operating income	-333 -20.8%	-276 -32.6%	-208 -40.8%	-148 -95.7%	-76 +8.1%	-82 -155.5%	-32 +10.6%	-36
Income tax	0	—	—	—	—	—	—	—
Net income	-329 -28.6%	-256 -33.0%	-192 -37.2%	-140 -94.0%	-72 +3.4%	-75 -135.0%	-32 +7.8%	-35
Basic EPS	-2.16 -11.3%	-1.94 +0.0%	-1.94 -12.1%	-1.73	—	—	—	—
Diluted EPS	-2.16 -11.3%	-1.94 +0.0%	-1.94 -12.1%	-1.73	—	—	—	—
Weighted average shares, basic	129 +24.1%	104 +30.4%	80 +35.6%	59	—	—	—	—
Weighted average shares, diluted	129 +24.1%	104 +30.4%	80 +35.6%	59	—	—	—	—
Other measures
Depreciation and amortization	3 +4.0%	2 +8.7%	2 +187.5%	1 +444.2%	0 -79.6%	1 -44.3%	1 -2.1%	1
EBITDA	-331 -21.0%	-273 -32.8%	-206 -40.0%	-147 -95.0%	-75 +7.5%	-81 -163.8%	-31 +11.0%	-35
Interest coverage	-108.87x	—	—	—	—	—	—	—
Margins
Operating margin	—	—	—	—	—	-1,044.33%	-143.02%	-369.89%
Profit margin	—	—	—	—	—	-950.43%	-141.49%	-354.76%
EBITDA margin	—	—	—	—	—	-1,035.18%	-137.27%	-356.32%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: COGT (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Waltham, MA
SEC filer status: Large accelerated filer
SEC CIK: 1622229
Former names: Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.